QLT Announces Fourth Quarter and Year End 2014 Results
Provides Strategic Review and Synthetic Retinoid Program Update
JAN. 5
QLT to Appoint Glen Ibbott as Interim Chief Financial Officer
dec. 16
QLT Announces Results of Annual General Meeting of Shareholders
Provides Update on Strategic and Business Review
dec. 5
QLT Announces Results from Proof-of-Concept Trial with Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects with Impaired Dark Adaptation and/or Impaired Low Luminance Vision
2014 Proxy Materials and Annual Report For the 2014 Proxy Statement and Annual Report for the fiscal year ended December 31, 2013, click here
Sept. 13
Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT
HEAD OFFICE: QLT Inc., 887 Great Northern Way, Suite 250, Vancouver, BC, Canada, V5T 4T5 | t 1.877.764.3131
